Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk large B-cell lymphoma. Patients with high-risk large B-cell lymphoma (LBCL) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback